NORDIC LYMPHOMA GROUP (NLG): STATUTES SEPTEMBER 2018

§1 PURPOSES

To promote research into the epidemiology, biology and treatment of malignant lymphoma in the Nordic countries (Sweden, Norway, Finland and Denmark).

§2 ORGANIZATION

2.1 NLG is an independent organization, consisting of a coordinating group, study centres and several working groups.

2.2 The Coordinating Group (NLG-CG) is the executive organ of the NLG. It coordinates the activities of the working groups. CG is also deciding upon applications to become NLG Study Centre (NLG-SC)
The NLG-CG consists of eight persons, two from each participating country. It is recommended that these are elected by the national lymphoma group of each country, and that at least one of the two national CG members are represented in the national lymphoma group, in order to facilitate implementation of NLG initiatives in each country. The NLG-CG constitutes itself with a chairman, a vice chairman. The chairman will typically be in office for a period of four years. It is recommended that the chair rotates between the countries. To secure continuity it is recommended that a chairman serves as vice chairman the two years before his chair ("chairman-elect") and two years after his chair to support the new chairman.
.

The NLG-CG will assemble at least once annually, in addition to at least one annual telephone meeting. Representatives from the NLG organisation may participate when needed. Prior to any such meeting an agenda must be circulated by the chairman to the members in due time. Decisions of the NLG-CG are made by simple majority. A member who cannot take part in a meeting may give the chairman a written mandate to vote on specific items on the agenda or send a substitute representative of the national lymphoma group.

It is the responsibility of the NLG-CG to arrange annual plenary meetings with all working group members and representatives from the NLG-SC, sponsors and, for other care givers of lymphoma patients

The NLG-CG should assure adequate communication between the members of the NLG-SC via the homepage and Newsletters distributed through the national lymphoma groups.

2.3 A NLG working group (NLG-WG) typically consists of four to eight persons, one-two from each participating country. It is recommended that the members are elected by the national lymphoma group of each country. Members of the NLG organisation may not be affiliated with the medical industry. It is recommended that each NLG-SC only have one representative in each NLG-WG, and to ensure as broad recruitment as possible, it is generally not recommended that a person is a member of more than one NLG-WG at a time. Each WG constitutes itself with a chairman unanimously. If more candidates are present, the CG will elect the WG Chairman of the group. The WG can invite non-WG member to the meetings. The NLG-WGs are initiated by the NLG-CG when the need for research into a certain topic, reflecting a biological

lymphoma entity or a cross-sectional topic throughout entities (e.g. epidemiology WG), is formulated. The purpose of a NLG-WG is primarily to promote research, secondarily to formulate existing knowledge into Nordic reference programs. When the NLG-WG is planning a new study, or participation in an intergroup project, the NLG-WG will present the proposal at the next plenary meeting. A NLG-WG may apply for economical support to hold one or two additional NLG-WG meetings per year within the Nordic region.

2.4 A NLG Study Centre (NLG-SC) is a department/hospital accredited by the NLG-CG and agree to fulfil the following rules:

1. During the preparation of a new protocol the NLG study centers must report their plans regarding participation in the protocol when requested by the working group. The decision about the launching of a protocol or the participation in a multinational and/or company-initiated study will be taken by the working group, based on the interest among the study centers
2. Once a center has officially accepted to participate in a study, it is encouraged to include all patients who fulfill the inclusion criteria in the study.
3. An NLG study center commits itself to try to create appropriate logistic conditions that will facilitate the participation in NLG studies. Within the limits of its resources, NLG will be of assistance in this process.

2.5. NLG has a clinical trial office (NLG-CTO), whose purpose is to facilitate the implementation of investigator-initiated NLG trials by providing support within topics such as e-CRF design, application to medical authorities, randomization, pharmacovigilance, coordination between study PI and participating sites, monitoring plan, juridical assistance, annual safety reports, protocol amendments etc, The NLG-CTO is located at one of the NLG-SC. The NLG-CG is the overall responsible

§3 ECONOMY

3.1 The NLG seeks its financial support from public and private funds and from sponsorships from the medicinal industry. Sponsorships must be defined in sponsor contracts guaranteeing the scientific independence of the NLG. The applications for funds for the annual plenary meeting is the responsibility of the NLG-CG.

3.2 To the purpose of tax exemption, any funding’s or sponsor support received must be placed in a institutional account, accounted for by the national revenue.

3.3 The account is monitored by the chairman, who will present an annual balance to the NLG-CG and at the Business meeting.

§4 CHANGE OF STATUTES

The statutes of the NLG may be changed by a simple majority in the NLG-CG.